# Adopting a Collaborative Strategy to Address the Complexities of Implanting a Subcutaneous Implantable Cardiac Defibrillator for Secondary Prevention in a Patient With Fabry Disease and Motor Neuron Disease

**Authors:** Sumantra Kumar De, Elton Luo, Adnan Ahmed, Padmanabhan Shakkottai, Renjith Antony

PMC · DOI: 10.7759/cureus.79379 · Cureus · 2025-02-20

## TL;DR

A patient with rare diseases received a subcutaneous defibrillator after a cardiac arrest, requiring a collaborative approach to ensure safety and quality of life.

## Contribution

Highlights a multidisciplinary strategy for managing implantable defibrillators in patients with complex, overlapping rare diseases.

## Key findings

- The patient successfully recovered after S-ICD implantation despite multiple coexisting conditions.
- Collaboration among specialties was essential to balance medical needs and quality of life.
- The approach reduced infection risk while providing necessary cardiac protection.

## Abstract

A man in his mid-40s, diagnosed with motor neuron disease (MND) and Fabry disease (FD), was sent to cardiology after experiencing a cardiac arrest at home secondary to ventricular fibrillation (VF). Fabry disease is a rare X-linked inherited lysosomal storage disorder caused by deficient alpha-galactosidase A (AGAL-A) activity that leads to an accumulation of globotriaosylceramide (Gb3) in affected tissues, including the heart. Motor neuron disease is an uncommon condition that progressively damages parts of the nervous system. He experienced a positive neurological recovery, enabling the cardiology team to investigate the cause of his arrest. Despite his considerable coexisting health issues and reliance on medical and non-medical interventions, he seemed to enjoy a good quality of life. By working together, the multidisciplinary team, alongside the patient and their family, reached an agreement on the treatment offered. In light of his ongoing medical conditions, the patient underwent a subcutaneous implantable cardioverter defibrillator (S-ICD) implantation to reduce the risk of infection while ensuring he got the relevant protection in the event of further life-threatening ventricular arrhythmia. He had a successful recovery, maintaining his quality of life and independence. Here, we describe the challenges involved in ensuring the best interest decision was taken, which required extensive collaboration from various specialties following a cardiac arrest.

## Linked entities

- **Chemicals:** globotriaosylceramide (PubChem CID 66616222), Gb3 (PubChem CID 5353448)
- **Diseases:** Fabry disease (MONDO:0010526), FD (MONDO:0010526), motor neuron disease (MONDO:0020128), ventricular fibrillation (MONDO:0000190), VF (MONDO:0000190)

## Full-text entities

- **Genes:** GLA (galactosidase alpha) [NCBI Gene 2717] {aka GALA}
- **Diseases:** X-linked inherited lysosomal storage disorder (MESH:D016464), VF (MESH:D014693), arrest (MESH:D006323), FD (MESH:D000795), MND (MESH:D016472), ventricular arrhythmia (MESH:D001145), infection (MESH:D007239)
- **Chemicals:** Gb3 (-), globotriaosylceramide (MESH:C018549)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11929588/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11929588/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC11929588/full.md

---
Source: https://tomesphere.com/paper/PMC11929588